Aveanna Healthcare Holdings Inc. (AVAH)

Operations and cash generation have improved materially, and recent SEC filings show no going-concern language and continued covenant compliance. However, leverage remains elevated and recent GAAP earnings include a large tax valuation-allowance release, making some headline profitability and valuation measures look stronger than the underlying run-rate. Combined with a low public float and sponsor/insider sell-down activity, this fits a watchlist/turnaround profile with meaningful risk rather than a low-volatility core holding.

Dominant catalysts: a market-rewarded Q2-2026 beat with raised FY2026 guidance (announced, 08-13; ~+41.6% rally) versus a fresh 15M-share J.H. Whitney secondary priced at $11.75 with no company proceeds (announced, 08-21); the sentiment delta is determinate but flat (+0.15 baseline → +0.10 scoring), the legal screen shows no fresh items, and moderate red-flag caps apply for the opportunistic supply overhang and the conflicting in-window catalyst signals.

Score 4 (strong setup, one weak signal): multiple bullish confirmations across trend, momentum and volume — price above SMA20/50/200 and EMA21, ADX14 at 52.1 and rising, RSI14 cooling from overbought (81 → 67), MACD line well above zero, avgDollarVolume20 ≈ $46.9M — while the structure-based R/R at the year-high breakout entry is 1.20 (below the 2.0 threshold for a 5) and the MACD histogram is marginally negative (-0.01) as momentum digests the mid-August surge.